BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 30372397)

  • 21. PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma.
    Walton J; Lawson K; Prinos P; Finelli A; Arrowsmith C; Ailles L
    Nat Rev Urol; 2023 Feb; 20(2):96-115. PubMed ID: 36253570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
    Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling Renal Cell Carcinoma in Mice:
    Gu YF; Cohn S; Christie A; McKenzie T; Wolff N; Do QN; Madhuranthakam AJ; Pedrosa I; Wang T; Dey A; Busslinger M; Xie XJ; Hammer RE; McKay RM; Kapur P; Brugarolas J
    Cancer Discov; 2017 Aug; 7(8):900-917. PubMed ID: 28473526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular genetics of clear-cell renal cell carcinoma.
    Brugarolas J
    J Clin Oncol; 2014 Jun; 32(18):1968-76. PubMed ID: 24821879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.
    Kroeger N; Klatte T; Chamie K; Rao PN; Birkhäuser FD; Sonn GA; Riss J; Kabbinavar FF; Belldegrun AS; Pantuck AJ
    Cancer; 2013 Apr; 119(8):1547-54. PubMed ID: 23335244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.
    Gao W; Li W; Xiao T; Liu XS; Kaelin WG
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1027-1032. PubMed ID: 28082722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
    Zhang X; Li S; He J; Jin Y; Zhang R; Dong W; Lin M; Yang Y; Tian T; Zhou Y; Xu Y; Lei QY; Zhang J; Zhang Q; Xu Y; Lv L
    Cancer Res; 2022 Jun; 82(11):2097-2109. PubMed ID: 35176127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.
    Takeda K; Bastacky S; Dhir R; Mohebnasab M; Quiroga-Garza GM
    Ann Diagn Pathol; 2024 Feb; 68():152223. PubMed ID: 37976977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential
    Mizutani K; Yokoi S; Sawada S; Sakamoto I; Kameyama K; Kamei S; Hirade K; Sugiyama S; Matsunaga K; Yamada T; Kato Y; Nishihara H; Ishihara S; Deguchi T
    Cancer Genomics Proteomics; 2022; 19(6):740-746. PubMed ID: 36316043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations in VHL as potential biomarkers in renal-cell carcinoma.
    Gossage L; Eisen T
    Nat Rev Clin Oncol; 2010 May; 7(5):277-88. PubMed ID: 20368728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
    Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
    BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer.
    Liao L; Liu ZZ; Langbein L; Cai W; Cho EA; Na J; Niu X; Jiang W; Zhong Z; Cai WL; Jagannathan G; Dulaimi E; Testa JR; Uzzo RG; Wang Y; Stark GR; Sun J; Peiper S; Xu Y; Yan Q; Yang H
    Elife; 2018 Oct; 7():. PubMed ID: 30355451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Benefit of Niraparib to TKI/mTORi-Resistance Metastatic ccRCC With
    Lian BJ; Zhang K; Fang XD; Li F; Dai Z; Chen WY; Qi XP
    Front Oncol; 2022; 12():927250. PubMed ID: 35875073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
    Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
    Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development.
    Duns G; Hofstra RM; Sietzema JG; Hollema H; van Duivenbode I; Kuik A; Giezen C; Jan O; Bergsma JJ; Bijnen H; van der Vlies P; van den Berg E; Kok K
    Hum Mutat; 2012 Jul; 33(7):1059-62. PubMed ID: 22461374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preliminary Study of Whole-Genome Bisulfite Sequencing and Transcriptome Sequencing in VHL Disease-Associated ccRCC.
    Li L; Bao H; Xu Y; Yang W; Zhang Z; Ma K; Zhang K; Zhou J; Gong Y; Ci W; Gong K
    Mol Diagn Ther; 2023 Nov; 27(6):741-752. PubMed ID: 37587253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
    Rosellini M; Mollica V; Marchetti A; Coluccelli S; Giunchi F; Tassinari E; Ricci C; Fiorentino M; Tallini G; De Biase D; Massari F
    Pathol Res Pract; 2024 Feb; 254():155142. PubMed ID: 38277752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Identification of Zinc-Finger Protein 433 as a Possible Prognostic Biomarker for Clear-Cell Renal Cell Carcinoma.
    Heyliger SO; Soliman KFA; Saulsbury MD; Reams RR
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective.
    Shenoy N; Pagliaro L
    Ann Oncol; 2016 Sep; 27(9):1685-95. PubMed ID: 27329246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.